HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Permyos Ruengsakulrach Permission Requests Google Scholar Articles by Arom, K. V Articles by Jotisakulratana, V. PubMed PubMed Citation Articles by Arom, K. V Articles by Jotisakulratana, V.

Intramyocardial Angiogenic Cell Precursor Injection for Cardiomyopathy

Cardiovascular Surgery, Bangkok Heart Hospital, Bangkok, Thailand

For reprint information contact: Kitipan V Arom, PhD, Tel: 66 2 310 3323, Fax: 66 2 310 3088, Email: karom{at}bangkokheart.com, Bangkok Heart Hospital, 2 Soi Soonvijai 7, New Petchburi Road, Bangkok 10320, Thailand.

Stem cell therapy for heart failure is a rapidly progressing field. The objective of this study was to assess the safety, and short-term results of thoracoscopic direct injection of angiogenic cell precursors into patients with endstage cardiomyopathy. Cells were obtained from the patient’s own blood, avoiding immunological concerns. The number of cells prior to injection was 29.1 ± 18.9 x10⁶. Forty-one patients with cardiomyopathy (mean age, 58.5 ± 14.3 years) underwent stem cell injection; 21 had dilated cardiomyopathy and 20 had ischemic cardiomyopathy. Overall ejection fraction improved significantly by 4.8% ± 7.5% at 149 ± 98 days postoperatively. It increased from 25.9% ± 8.6% to 28.7% ± 9.8% in dilated cardiomyopathy, and from 26.6% ± 5.8% to 33.6% ± 7.8% in ischemic cardiomyopathy. New York Heart Association functional class was significantly better at 2 months in both groups. It was concluded that thoracoscopic intramyocardial angiogenic cell precursor injection is feasible and safe in patients with cardiomyopathy. The early results are good, and phase II trials are in progress.